Literature DB >> 12103265

Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure.

Antti Kuoppala1, Naotaka Shiota, Jorma O Kokkonen, Inka Liesmaa, Karam Kostner, Mikko Mäyränpää, Petri T Kovanen, Ken A Lindstedt.   

Abstract

OBJECTIVES: We sought to study the expression of bradykinin type-2 receptors (BK-2Rs) in patients with heart failure (HF).
BACKGROUND: Recent work in experimental animals has suggested that bradykinin (BK) exerts cardioprotective effects through specific BK-2Rs. However, nothing is known about the regulation of BK-2R expression in the pathogenesis of human HF.
METHODS: Human heart tissue was obtained from excised hearts of patients undergoing cardiac transplantation (n = 13) and from normal hearts (n = 6) unsuitable for donation. The patients had HF due to idiopathic dilated cardiomyopathy (IDC) (n = 7) or coronary heart disease (CHD) (n = 6). Tissue samples from the left ventricles were analyzed by competitive reverse-transcriptase-polymerase chain reaction and Western blotting for the expression of BK-2R messenger ribonucleic acid (mRNA) and protein.
RESULTS: In both the IDC and CHD hearts, the level of BK-2R mRNA expression was found to be significantly lower (30% and 38% of control values, respectively) than that in normal hearts. Correspondingly, the BK-2R protein level was significantly reduced in both the IDC and CHD hearts (45% and 62% of control values, respectively) and apparently involved all myocardial cell types. The down-regulation of BK-2R expression in failing hearts did not correlate with decreased cellularity or with the expression pattern of other members of the G-protein-coupled receptor superfamily. However, BK-2R down-regulation in the failing hearts was associated with a decrease in endothelial nitric oxide synthase in both IDC (53% of control value) and CHD (43% of control value) hearts.
CONCLUSIONS: These results are the first to suggest that a loss of BK-2Rs is involved in the pathogenesis of human HF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12103265     DOI: 10.1016/s0735-1097(02)01928-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Statins and the myocardium.

Authors:  Seema Mital; James K Liao
Journal:  Semin Vasc Med       Date:  2004-11

2.  Bradykinin receptor blockade reduces sympathetic nerve response to muscle contraction in rats with ischemic heart failure.

Authors:  Satoshi Koba; Jihong Xing; Lawrence I Sinoway; Jianhua Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-05       Impact factor: 4.733

Review 3.  Statin therapy for cardiac hypertrophy and heart failure.

Authors:  James K Liao
Journal:  J Investig Med       Date:  2004-05       Impact factor: 2.895

4.  Simvastatin preserves cardiac function in genetically determined cardiomyopathy.

Authors:  Seena S Abraham; Juan C Osorio; Shunichi Homma; Jie Wang; Harshwardhan M Thaker; James K Liao; Seema Mital
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

5.  Bradykinin type-2 receptor expression correlates with age and is subjected to transcriptional regulation.

Authors:  Inka Liesmaa; Naotaka Shiota; Jorma O Kokkonen; Petri T Kovanen; Ken A Lindstedt
Journal:  Int J Vasc Med       Date:  2011-10-03

6.  Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Authors:  Prasad Gunaruwan; Abdul Maher; Lynne Williams; James Sharman; Matthias Schmitt; Ross Campbell; Michael Frenneaux
Journal:  Clin Sci (Lond)       Date:  2009-03       Impact factor: 6.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.